NCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated
Clinical Trials
12 trialsNCT04924075 2026-02-24
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT04711135 2026-02-12
NETTER-P
Advanced Accelerator Applications
Phase 2 Active not recruiting
NCT04187404 2026-01-30
Spencer
Enterome
Phase 1/2 Terminated
NCT05636618 2025-11-24
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
Perspective Therapeutics
Phase 1/2 Recruiting
NCT06233903 2025-01-21
18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Phase 2 Withdrawn
NCT01590680 2023-02-28
Expanded Access Protocol Using 131I-MIBG
Jubilant DraxImage Inc.
Available
NCT00874614 2020-02-20
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Phase 2 Unknown
NCT02961491 2019-01-30
Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Approved for marketing
NCT00458952 2016-07-13
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00911729 2013-06-10
Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Terminated
NCT00339131 2011-10-12
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Molecular Insight Pharmaceuticals, Inc.
Phase 1 Completed